These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35046292)

  • 1. [A Case of Unresectable Recurrent Colorectal Cancer with Regorafenib Treatment and Long-Term Survival].
    Maruo H; Sato S; Nakamura T; Sekimori K; Obayashi M; Hayashi Y; Ishimatsu H; Shoji T; Hirayama K; Yamazaki M
    Gan To Kagaku Ryoho; 2021 Dec; 48(13):1670-1672. PubMed ID: 35046292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report.
    Yoshino K; Manaka D; Kudo R; Kanai S; Mitsuoka E; Kanto S; Hamasu S; Konishi S; Nishitai R
    J Med Case Rep; 2017 Aug; 11(1):227. PubMed ID: 28818109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A Case of Long-Term Survival after Administration of Regorafenib for Stage Ⅳ Colorectal Cancer].
    Kono T; Yokokawa H; Miyano Y; Oyama K; Yoshimatsu K; Koike T; Shiozawa S
    Gan To Kagaku Ryoho; 2021 Oct; 48(10):1278-1280. PubMed ID: 34657063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiological complete response with regorafenib for multiple lung metastases of ascending colon cancer: a case report.
    Kikuchi K; Ogawa M; Sasaki A
    J Med Case Rep; 2024 Feb; 18(1):45. PubMed ID: 38321556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
    Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
    Köstek O; Hacıoğlu MB; Sakin A; Demir T; Sarı M; Ozkul O; Araz M; Doğan AF; Demircan NC; Uzunoğlu S; Çiçin İ; Erdoğan B
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):115-122. PubMed ID: 30374523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
    Bertocchi P; Aroldi F; Prochilo T; Meriggi F; Beretta GD; Zaniboni A
    J Chemother; 2017 Apr; 29(2):102-105. PubMed ID: 28032528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature.
    Zhang Y; Zhang F; Zhao L; Fu X; Shang Y; Gao Q
    BMC Gastroenterol; 2021 Oct; 21(1):399. PubMed ID: 34688262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.
    Al-Marrawi MY; Saroya BS; Brennan MC; Yang Z; Dykes TM; El-Deiry WS
    Cancer Biol Ther; 2013 Aug; 14(8):703-10. PubMed ID: 23792568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
    Eng C; Kim TW; Bendell J; Argilés G; Tebbutt NC; Di Bartolomeo M; Falcone A; Fakih M; Kozloff M; Segal NH; Sobrero A; Yan Y; Chang I; Uyei A; Roberts L; Ciardiello F;
    Lancet Oncol; 2019 Jun; 20(6):849-861. PubMed ID: 31003911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
    Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J
    Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review.
    Xie X; Zhang J; Hu H; Cai Y; Wu Z; Ling J; Li W; Deng Y
    Adv Ther; 2020 Oct; 37(10):4233-4248. PubMed ID: 32770529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells.
    Matsuoka K; Nakagawa F; Tanaka N; Okabe H; Matsuo K; Takechi T
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study.
    Ozaki Y; Shindoh J; Gonoi W; Nishioka Y; Kondoh C; Tanabe Y; Matoba S; Kuroyanagi H; Hashimoto M; Takano T
    BMC Cancer; 2018 Feb; 18(1):138. PubMed ID: 29402244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer.
    Adenis A; Mazard T; Fraisse J; Chalbos P; Pastor B; Evesque L; Ghiringhelli F; Mollevi C; Delaine S; Ychou M
    BMC Cancer; 2021 May; 21(1):564. PubMed ID: 34001059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-Term Survival of a Patient with Metastatic Liver and Para-Aortic Lymph Node Cancer from Colon Cancer Treated with Regorafenib].
    Watanabe N; Akagi S; Inoue H; Nakatsuji H; Ito H; Toma A; Nakamura K; Ochiai T; Otsuji E
    Gan To Kagaku Ryoho; 2017 Nov; 44(12):1732-1734. PubMed ID: 29394758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage Therapy After Regorafenib or Trifluridine/Tipiracil Treatment of Metastatic Colorectal Cancer: A Conditional Landmark Analysis.
    Nakashima M; Takeuchi M; Tanaka S; Kawakami K
    Anticancer Res; 2021 Feb; 41(2):1055-1062. PubMed ID: 33517315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
    Sanoff HK; Goldberg RM; Ivanova A; O'Reilly S; Kasbari SS; Kim RD; McDermott R; Moore DT; Zamboni W; Grogan W; Cohn AL; Bekaii-Saab TS; Leonard G; Ryan T; Olowokure OO; Fernando NH; McCaffrey J; El-Rayes BF; Horgan AM; Sherrill GB; Yacoub GH; O'Neil BH
    Cancer; 2018 Aug; 124(15):3118-3126. PubMed ID: 29905927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: Clinical case report of a long-responder patient treated with regorafenib beyond progression.
    Roberto M; Falcone R; Mazzuca F; Archibugi L; Castaldi N; Botticelli A; Osti MF; Marchetti P
    Medicine (Baltimore); 2017 Dec; 96(48):e9023. PubMed ID: 29310420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
    Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
    Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.